Sonnet BioTherapeutics Q3 2024 GAAP EPS $(0.70) Beats $(0.76) Estimate
Portfolio Pulse from Benzinga Newsdesk
Sonnet BioTherapeutics (NASDAQ:SONN) reported a Q3 2024 GAAP EPS of $(0.70), beating the analyst consensus estimate of $(0.76) by 7.89%.
August 14, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sonnet BioTherapeutics reported a Q3 2024 GAAP EPS of $(0.70), which is better than the analyst consensus estimate of $(0.76). This positive earnings surprise may boost investor confidence in the short term.
The better-than-expected earnings per share (EPS) indicates that the company is performing better than analysts anticipated, which is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100